Clinical Trial: Efficacy and Safety of Mirogabalin in Uremic Pruritus

U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936292) titled 'Efficacy and Safety of Mirogabalin in Uremic Pruritus' on Nov. 07.

Brief Summary: This study aims to assess the efficacy and safety of mirogabalin in alleviating moderate-to-severe uremic pruritus in patients undergoing maintenance hemodialysis, and to establish the optimal dosing frequency by comparing continuous daily administration against intermittent post-dialysis administration.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Uremic Pruritus

Intervention: DRUG: Mirogabalin (Intermittent)

Patients will receive mirogabalin 5 mg three times per week, administered immediately after each hemodialysis sessi...